SEC Form 4 · accession 0001610717-26-000351
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alejandra Carvajal
Officer — Chief Legal Officer
Period of report
Aug 3, 2026
Accepted (ET)
Aug 5, 2026 · 7:33 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001501989
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 3, 2026 | A | 100,000 | $0.00 | A | 100,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $3.17 | Aug 3, 2026 | A | 450,000 | A | — | Aug 2, 2036 | Common Stock | 450,000 | 450,000 | D |
Explanation of responses
- F1Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on September 15 of each year, with the first 25% vesting on September 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such date.
- F2Includes 100,000 RSUs.
- F325% of the shares subject to the option vest on the one-year anniversary measured from August 3, 2026 (the "Vesting Commencement Date"), and 1/48 monthly thereafter such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.